图布利斯获得了全球对生物细胞原体人类抗体的权利,以发展抗癌的ADC。 Tubulis gains global rights to Biocytogen’s human antibody for cancer-fighting ADC development.

生物细胞素制药公司宣布,Tubulis是一名抗体药物共产物(ADC)开发商,已经获得全球独家许可证,允许使用RenMice平台使用生物细胞素制造的完全人体抗体。 Biocytogen Pharmaceuticals has announced that Tubulis, an antibody-drug conjugate (ADC) developer, has secured an exclusive global license to a fully human antibody created by Biocytogen using its RenMice® platform. 以高亲近性和低免疫力著称的抗体将被用于Tubulis开发的新型ADC候选体,利用它独家的连接器和有效载荷技术。 The antibody, noted for high affinity and low immunogenicity, will be used in a novel ADC candidate developed by Tubulis, leveraging its proprietary linker and payload technologies. 合作起源于先前的一项研究协定,目的是推进ADC癌症治疗,目标是解决大量未得到满足的医疗需求。 The collaboration stems from a prior research agreement aimed at advancing ADC therapies for cancer, with the goal of addressing significant unmet medical needs.